Cocrystal Pharma holders back board and auditor
Cocrystal Pharma, Inc. held its 2026 Annual Meeting of Stockholders on July 14, 2026.
Rhea-AI Filing Summary
Cocrystal Pharma, Inc. held its 2026 Annual Meeting of Stockholders on July 14, 2026. Stockholders voted on electing five directors, ratifying the independent auditor for the fiscal year ending December 31, 2026, and a possible adjournment to solicit additional proxies if needed.
All five director nominees were elected, with votes for each ranging from 5,914,522 to 6,293,331, and 2,860,552 broker non-votes recorded for each nominee. Stockholders ratified Weinberg & Company as the independent registered public accounting firm, with 9,181,034 votes for, 174,923 against, and 10,587 abstentions. Because Proposals 1 and 2 received sufficient support, the adjournment proposal was moot.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
broker non-votes regulatory
independent registered public accounting firm regulatory
definitive proxy statement regulatory
adjournment regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Cocrystal Pharma (COCP) stockholders vote on at the 2026 Annual Meeting?
Were all director nominees elected at Cocrystal Pharma (COCP)’s 2026 Annual Meeting?
How did Cocrystal Pharma (COCP) stockholders vote on ratifying Weinberg & Company as auditor?
What are broker non-votes reported in Cocrystal Pharma (COCP)’s 2026 director elections?
What happened to the adjournment proposal at Cocrystal Pharma (COCP)’s 2026 Annual Meeting?
Who is serving as Cocrystal Pharma (COCP)’s independent registered public accounting firm for 2026?
AI-generated analysis. How Rhea-AI works. Not financial advice.